Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to examine whether co-administration of rifampin with neratinib has an effect on the pharmacokinetics (how the body absorbs, distributes, metabolizes and/or excretes) of neratinib.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Neratinib alone |
|
| 2 | Experimental | Neratinib plus rifampin |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Neratinib | Drug | HKI-272 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics (plasma blood concentrations) | 4 weeks |
Not provided
Not provided
Inclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Puma | Biotechnology | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Miami | Florida | 33126 | United States |
Not provided
| ID | Term |
|---|---|
| C487932 | neratinib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided